(Date:12/10/2009)... Dec. 10 Dendreon Corporation (Nasdaq: DNDN ... public offering of 15,000,000 shares of its common stock ... share. Dendreon also granted to the underwriters a ... shares of common stock to cover overallotments, if any. ... 15, 2009, subject to customary closing conditions. ,, J. ...
(Date:12/10/2009)... the National Institutes of Health (NIH), awarded a $2.18 million ... a non-invasive, passive diffusion-based treatment for severe, non-infectious uveitis. ... ... UT (PRWEB) December 10, 2009 -- The National Eye Institute ... awarded a $2.18 million grant to Aciont Inc. to help ...
(Date:12/10/2009)... BioSciences Inc. (NYSE Amex: YMI ; TSX: ... identifies and advances a diverse portfolio of promising ... provided an update on the proposed transaction which ... into YM, details of which were announced on ... Cytopia has unanimously recommended that its shareholders vote ...
(Date:12/10/2009)... CORALVILLE, Iowa, Dec. 10 Vivakor, ... that it has entered into an exclusive, ... specialist, Regeneca International, Inc. ( www.regeneca.com ). ... distribution rights to a new cutting-edge nutraceutical ... the development of future formulations by Vivakor ...
Breaking Biology Technology:Dendreon Announces Pricing of Common Stock Offering 2Dendreon Announces Pricing of Common Stock Offering 3NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 2NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 3YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 2YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 3YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 4Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 2Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 3... Corporation, a leading manufacturer of next-generation portable lasers ... increased dramatically in 2008 over 2007. The company,s ... helped to more than offset current economic conditions, ... sales month for Aerolase, and 2008 overall represented ...
... Jan. 23 Peter T. Wilderotter, president and CEO ... following statement today in response to FDA clearance of ... is an exciting first step for Geron and for ... to advances in medical research. There has been so ...
... Spinal Cord Injury , Geron Corporation ... and Drug,Administration (FDA) has granted clearance of the company,s Investigational,New ... patients with,acute spinal cord injury. The clearance enables Geron to ... stem (hESC) cell-based therapy,in man. , ...
Other Biology Technology:Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers 2Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers 3Christopher and Dana Reeve Foundation Response to FDA Clearance of Geron's Clinical Trial 2MultiVu Video Feed: Geron Receives FDA Clearance to Begin World's First Human Clinical Trial of Embryonic Stem Cell-Based Therapy 2Request Info...
Anti-Rat KAPPA/LAMBDA:HRP, Clone MARK-1/MARL-15, Monoclonal Antibody...
For the development of an immunoprecipitation assay to measure Chk1 kinase activity in cell lysates....
SAIVI Alexa Fluor 680 injectable contrast agent *bovine serum albumin*...
Biology Products:Biology NavigationMedical Navigation